⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20483456 | 0.96 | — | — | |
| SCHEMBL2476298 | 0.96 | — | — | |
| SCHEMBL20483454 | 0.96 | — | — | |
| SCHEMBL2096291 | 0.90 | — | — | |
| SCHEMBL17980207 | 0.90 | — | — | |
| SCHEMBL4995911 | 0.87 | — | — | |
| SCHEMBL4995905 | 0.87 | — | — | |
| SCHEMBL2492666 | 0.85 | — | — | |
| SCHEMBL15855789 | 0.80 | — | — | |
| SCHEMBL25395957 | 0.77 | HSD17B10 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951821-B2 | Devoided of activity on the opiate or 5-HT3 receptors, exhibit a particular activity as specific inhibitors of the glycine transporters glyt1 and/or glyt2; 2-Chloro-N-[(S)-phenyl-[(2S)-piperidin-2-yl]methyl]-3-(trifluoromethyl)benzamide | SANOFI-AVENTIS (FR) | 2011-05-31 | — | — | US | disclosed |
| US-7750025-B2 | Derivatives of N-phenyl (piperidine-2-yl) methyl benzamide, preparation method thereof and applications of same in therapeutics | SANOFI-AVENTIS (FR) | 2010-07-06 | — | — | US | disclosed |
| US-7205319-B2 | exhibit a particular activity as specific inhibitors of the glycine transporters glyt1 and/or glyt2 | SANOFI-AVENTIS (FR) | 2007-04-17 | — | — | US | disclosed |
| US-20060223885-A1 | Derivatives of N-phenyl (piperidine-2-yl) methyl benzamide, preparation method thereof and applications of same in therapeutics | SANOFI-AVENTIS (FR) | 2006-10-05 | — | — | US | disclosed |